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Abstract
Objective—To explore the effects of providing unrestricted access to emergency contraception in
advance of need on various psychosocial outcomes and pregnancy.
Methods—In the trial, women were randomized to either increased access to emergency
contraception (two free packs at enrollment with unlimited free re-supply) or standard access.
Participants were evaluated for 1 year for pregnancy and other outcomes. Psychosocial data were
collected at enrollment and at 6 and 12 months. We applied exploratory factor analysis for data
reduction. We compared the resulting psychosocial factors (including factors related to “aversion to
pregnancy” and to the perceived “relative benefit” and “accessibility” of emergency contraception),
two items directly assessing substitution, and pregnancy between randomization groups over time.
Results—On average, women in the increased access group had significantly stronger perceptions
of both the “relative benefit” and “accessibility” of emergency contraception (p<0.001 for each).
Women in the increased access group were significantly more likely to report that they had ever used
emergency contraception because they did not want to use either condoms or another contraceptive
method (p<0.001). Regarding pregnancy, we noted a significant interaction between randomization
group and “aversion to pregnancy” (p=0.010): among the least “averse” women, increased access
had a protective effect (hazard ratio = 0.64, 95% confidence interval 0.39 to 1.04); among the most
“averse” women, increased access had a deleterious effect (hazard ratio = 1.73, 95% confidence
interval 1.01 to 2.98).
Conclusion—As a result of having unrestricted access, some women substituted emergency
contraception for their usual contraceptive methods.
Clinical Trial Registration—ClinicalTrials.gov, www.clinicaltrials.gov, NCT00060463
INTRODUCTION
Results from at least 14 comparative studies have provided no convincing evidence that
increased access to emergency contraception (EC) reduces the risk of unintended pregnancy
(1). On the other hand, previous studies also have not found that increased EC access adversely
affects self-reported coital or contraceptive use patterns (2) and, in fact, three trials have shown
that it does not increase risk of sexually transmitted infection (3-5). Furthermore, most of these
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studies provided evidence that increasing access encourages both more frequent and more
prompt use of EC following unprotected intercourse (2). Given these findings, some authors
have concluded that providing EC in advance of need is wholly beneficial (6). Recently
published international family planning guidelines have advocated universal application of this
approach (7). However, based on data from a randomized trial, we recently concluded that
some women most likely increased their risk of unintended pregnancy as a direct consequence
of having unrestricted access to EC (8).
Here, we describe new findings from this same trial. We conducted these secondary analyses
to investigate the effects of providing unrestricted access to EC on women’s attitudes and
practices regarding reproductive health, use of EC, and use of other contraceptive methods.
Our a priori null hypothesis was that the randomization groups would not differ, either overall
or within any important subgroups, with respect to any of the outcomes being explored.
METHODS
We conducted an unblinded randomized trial in Nevada and North Carolina between October
2002 and June 2005. The protocol was approved by the institutional review boards of the
University of California at San Francisco and Family Health International. Details of the trial
methods and primary results have been presented previously (5). In brief, we enrolled 1,490
sexually active women aged 14 to 24 years who did not desire pregnancy and who did not plan
to use long-acting contraceptive methods within the subsequent year. At the enrollment visit,
women completed a computer-assisted self-interview that collected relevant baseline data and
that also included a set of 27 reproductive health knowledge and attitude items (Figure 1).
These items covered the topics of pregnancy, sexually transmitted infections, condoms, birth
control pills, EC, and abortion. To minimize missing data, we programmed the computer to
require subjects to answer all questions. Women were then randomized into one of two groups
in a one-to-one ratio, stratified by site, using sequentially-numbered, opaque, sealed envelopes.
Women assigned to the increased access group received two free packs of EC at enrollment
with unlimited free re-supply throughout the study; women assigned to the standard access
group were advised about getting EC from the study site at usual charge when needed. The
trial sample size was based on the power for comparing the incidence of pregnancy and sexually
transmitted infections between groups (5).
During scheduled visits at approximately 6 and 12 months post-randomization, women
completed a computer-assisted self-interview that included the same 27 reproductive health
items asked at enrollment plus 16 additional items specifically related to EC (Figure 2). This
interview also asked two direct questions about whether, since joining the study, the participant
had “ever used emergency contraceptive pills because [she] did not want to use” a condom or
another contraceptive method. Responses to these two items were scored as 0 = “never,” 1 =
“once,” 2 = “a few times,” and 3 = “many times.” We also collected data on all pregnancies
and each self-reported use of EC throughout the study.
The analyses reported here included all women who contributed data to the primary pregnancy
analysis, specifically 724 and 717 women in the increased and standard access groups (5),
respectively, except for one woman in the increased access group whose baseline self-interview
data were lost due to a computer error. We considered 6- or 12-month visits to be any visit that
occurred either between 5 and 7 months or between 12 and 14 month post-randomization,
respectively, and we excluded data from any visits that occurred outside of these windows.
We used exploratory factor analysis as a method of data reduction prior to subsequent analyses.
Exploratory factor analysis is a statistical method that sorts a large set of questionnaire items
into internally-correlated subsets, each of which is assumed to represent an unobserved,
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underlying concept, called a “factor.” The nature of each factor is subjectively deduced by
examining the content of the items in the respective subset. For each participant, one can then
estimate a factor score, which signifies her level of congruence with the associated underlying
concept. These estimated factor scores can be used as outcomes or predictors in subsequent
analyses.
Using only the enrollment data, we first conducted a factor analysis using all 27 reproductive
health items (Figure 1). We reverse-scored indicated items so that higher scores always
represented a stronger desire or more self-efficacy to prevent either pregnancy or sexually
transmitted infection. We used subjective methods (a screen plot of the eigen values (9)) to
determine a minimal number of factors that would account for most of the covariation in the
original responses. We applied a recommended approach (principal factor analysis followed
by an oblique promax rotation (9,10)) to obtain our final solution. We excluded items that either
did not sort into any factor or that sorted into more than one factor. As a validation of our
solution, we repeated the factor analysis using data from the two follow-up visits separately,
but we derived all estimated factor scores for subsequent analyses using the scoring coefficients
obtained from the enrollment data.
Similarly, we conducted separate exploratory factor analyses with the 19 EC items (Figure 2)
for each treatment group at each follow-up visit. Based on these four analyses, we determined
the number of factors and items to be retained; items that were not consistently sorted into a
single factor were excluded. Using the reduced item pool, we then fit a factor analysis to the
6-month data for the standard access group alone to eliminate any effects of treatment or time.
We used the resulting scoring coefficients to derive estimated factor scores for both groups at
both visits. Factor scores were transformed back to the original item scale to aid interpretation.
We investigated the effect of our intervention with respect to the following outcomes: 1) the
reproductive health psychosocial factor scores; 2) the EC psychosocial factor scores; 3) the
two individual items about substitution of EC for other methods, as well as a combined
substitution outcome defined as the maximum response on the two items; and 4) the incidence
of pregnancy. To investigate group differences over time while controlling for within-subject
correlation, we applied general linear mixed models with unstructured covariance matrices
separately for each factor score. We used generalized estimating equation methods with an
identity link function and an unstructured working correlation matrix to analyze the combined
substitution outcome over time. Each model included terms for visit, treatment, and the visit-
by-treatment interaction and was adjusted for all baseline variables listed in Table 1. To explore
both the overall effects of increased access as well as any effect modification across important
subgroups of women, we first fit a full model that included all of the two-way interactions
between the baseline variables and treatment group. We tested the need for all interaction terms
simultaneously; if that test was not significant, we used a reduced model without interactions
for treatment group comparisons. However, if the overall interaction test was significant, our
final model included any interaction terms that were individually significant in the full model.
For the analysis of pregnancy, we used a Cox proportional hazards model, stratified by site, to
explore interactions between treatment group and baseline covariates. However, given the
relatively small number of pregnancies (67 in the increased access group and 70 in the standard
access group), we used a two-step model-building strategy. We first fit a model containing all
baseline covariates listed in Table 1, and we used a likelihood ratio test to eliminate non-
significant terms. We then tested whether any two-way interactions with treatment group could
significantly improve the fit of this reduced model using a second likelihood ratio test. The
final model included all significant covariates from the first step and all significant interactions
from the second step. We investigated violations to the proportional hazards assumption by
adding interactions with time and using a likelihood ratio test. We conducted all tests at the
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two-sided 5% significance level. All analyses were performed using SAS, Version 9.1 (SAS
Institute, Cary, NC).
RESULTS
In the increased access group, 565 of 723 women in the analysis population (78%) contributed
interview data from both follow-up visits, 115 (16%) contributed data from only one visit, and
43 (6%) contributed no interview data. In the standard access group, the corresponding values
were 573 of 717 women (80%) with both visits, 117 (16%) with one visit, and 27 (4%) with
no interview data.
The factor analysis of the 27 baseline reproductive health items (Figure 1) arranged 14 of the
items into four subsets assumed to represent underlying psychosocial factors; the other 13 items
were excluded. This four-factor solution accounted for almost 100% of the covariation among
the original responses. Based on the content of the items in each subset, we named the factors
“perceived contraceptive efficacy,” “aversion to pregnancy,” “access to contraception,” and
“stigma.” The results of separate factor analyses with the 6- and 12-month data were almost
identical to those for the baseline data, providing some validation of our final solution. For the
EC items (Figure 2), factor analyses consistently resulted in a two-factor solution that explained
almost 100% of the covariation among the original responses. Six items were consistently
arranged into the first factor, seven into the second factor, and six items into neither factor.
Based on the item subsets, we named the factors “EC relative benefit” and “EC accessibility.”
The estimated scores for these two EC factors were not significantly correlated; however, “EC
relative benefit” was significantly correlated with responses to each of the two contraceptive
substitution items, with estimated correlations of approximately 0.3.
Enrollment data (Table 1) from the analysis population are similar to those presented previously
for the entire randomized population (5). The groups were similar at baseline with respect to
the reproductive health psychosocial factors; participants in both groups tended to agree on
average with the items (reversed where indicated) in the “perceived contraceptive efficacy,”
“aversion to pregnancy,” and “access to contraception” factors, whereas they tended to disagree
on average with the items in the “stigma” factor (Figure 1). The groups did not differ
significantly with respect to any of the reproductive health factors at either follow-up visit
(Table 2), and we found no evidence of treatment effects within any subgroups of the
population.
The groups differed significantly in their responses to the two questions about substitution of
EC for condoms or other methods (Table 3). At each visit, women in the increased access group
were approximately three times as likely as women in the standard access group to report that
they had ever substituted. Among women who had data for both follow-up visits and who ever
reported substituting, 42% and 45% in the increased and standard access groups, respectively,
reported a greater frequency of ever substituting at 12 than at 6 months, suggesting that
substitution was not simply an immediate post-randomization occurrence.
For the combined substitution outcome (the maximum response on the two individual
substitution questions), we noted a significant interaction (p<0.001) between treatment group
and contraceptive method used at baseline (hormonal method, consistent condoms, or neither).
Consequently, although women in the increased access group were more likely to report
substituting with EC at both follow-up visits regardless of contraceptive method used at
baseline, the effect was most pronounced among women who neither used a hormonal method
nor were consistent condom users at baseline (Table 4).
The groups differed significantly with respect to the “EC relative benefit” factor at both visits;
women in the increased access group perceived greater average benefit of EC use (Table 4).
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The groups also differed significantly with respect to all six component items of the “EC
relative benefit” factor at both visits (all Mantel-Haenszel p-values, controlling for site, were
less than 0.01; item means for the 6-month visit are not shown but are similar to those for the
12-month visit presented in Figure 2). Women in the increased access group also had higher
“EC accessibility” scores on average than women in the standard access group (Table 4),
suggesting that our increased access intervention enhanced women’s perceptions of the ease
of obtaining and using EC. This effect was significantly more pronounced at the North Carolina
site than at the Nevada site, and it was observed in unmarried women but not in the small
proportion of married women in our sample.
We conducted some additional analyses to investigate the validity of the substitution questions.
The median number of reported EC uses tended to increase with the reported frequency of
substitution in both groups (Table 5), as would be expected. In both groups combined,
pregnancy rates increased significantly with increasing frequency of substitution (Cochran-
Armitage trend test p-value=0.01); however, this result must be interpreted with caution
because the order of the reported substitution and pregnancy was impossible to determine in
most cases. However, we found evidence that the substitution data may not be entirely valid.
Some women in each group reported fewer EC uses than would be implied based on their
responses to the substitution items (Table 5). In addition, some women provided inconsistent
responses to these items over time, but the relative frequency of these inconsistencies was
similar in the two groups: among women who had data for both follow-up visits and who
reported any substitution in the first 6 months, 38% and 39% in the increased and standard
access groups, respectively, reported more substitution at 6 than at 12 months.
Examining pregnancy incidence, we noted a significant interaction between the “aversion to
pregnancy” factor and treatment group (p=0.010): the effect of increased access to EC on
pregnancy risk was inversely related to a woman’s “aversion to pregnancy.” For example,
among women with an estimated “aversion to pregnancy” score at the 10th percentile (i.e., the
least “averse” women), increased access to EC decreased the risk of pregnancy relative to
standard access (hazard ratio = 0.64, 95% confidence interval 0.39 to 1.04). In contrast, among
women with an estimated “aversion to pregnancy” score at the 90th percentile (i.e., the most
“averse” women), increased access to EC actually increased the risk of pregnancy relative to
standard access (hazard ratio = 1.73, 95% confidence interval 1.01 to 2.98). Our model
controlled for previous pregnancy, Hispanic ethnicity, and contraceptive method used at
baseline. We found no evidence that the proportional hazards assumption was violated for this
model.
DISCUSSION
Our results provide a possible explanation for the failure of our EC access intervention to
produce a measurable decrease in unintended pregnancies. We found compelling evidence that
women who received increased access were more likely than women who received standard
access to substitute EC for their usual contraceptive method, even though we were unable to
directly measure the extent or nature of that substitution. Substituting EC for a more efficacious
contraceptive method, such as regular hormonal contraception or condoms, would increase the
risk of unplanned pregnancy. In contrast, use of EC after acts that otherwise would have been
either completely or partially unprotected would decrease risk. These two effects could easily
have offset each other, thus creating no measurable population-level impact on pregnancy rates.
This conclusion is entirely consistent with that drawn from our previously published analysis
from the same study (8). There, we observed that a greater proportion of the pregnancies in the
increased access group than in the standard access group were either probably or possibly the
result of EC failure. Given this, we reasoned that the women in the increased access group as
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a whole likely had more acts for which EC was used in place of a more effective contraceptive
method.
Here, we base our conclusion on the totality of our results rather than on any individual finding.
Our data do not allow us to identify precisely which participants substituted EC for other
contraceptive methods or when they may have done so. Although we refer to the two questions
summarized in Table 3 as “EC substitution items,” these questions were not pre-tested and
participants may not have interpreted them as asking explicitly about substitution, as we had
intended. Nevertheless, our data provide consistent evidence to support our conclusion. The
items that contributed to the factor we subjectively named “EC relative benefit” (Figure 2)
emphasize the utility of EC compared to other contraceptive methods; in fact, two of these
items specifically describe substitution scenarios. Thus, an alternative name for the latent
concept measured by this subset of items might be “propensity to substitute.” The positive
correlations between this factor and the direct substitution questions provide some evidence
of the validity of this interpretation. Furthermore, because the factor items asked about current
attitudes, they were not subject to recall bias, unlike the substitution questions. Indeed, this
factor might very well be a more reliable measure of a propensity to substitute than responses
to the direct substitution questions.
Although our intervention did not measurably affect pregnancy risk across the entire study
population, if it encouraged some women to substitute EC for more effective contraceptive
methods, then it caused an increase in pregnancy risk for those acts for those women. The
concern that our intervention was hazardous to some women is supported by our analysis of
pregnancy. We found that our intervention increased the pregnancy risk among women who
were most averse to pregnancy but decreased risk among women who were the least averse.
Although our analysis did not specifically link this finding to EC substitution, this finding
provides further evidence that the effect of unrestricted access was not uniform across the study
population.
Consistent with results from other studies, our primary analysis of this trial found no evidence
of a treatment effect on self-reported sexual behavior or use of contraceptive methods other
than EC (5). However, one should not infer from those results that unrestricted access to EC
had no effect on contraceptive behaviors. First, and most importantly, non-significant statistical
tests can never provide persuasive evidence in favor of the null hypothesis. Additionally, self-
reported sexual behavior data have been found to be of questionable validity (11). Thus,
although the findings presented here are different from those of the primary analyses (5), the
two are not necessarily incompatible.
Our analysis has limitations. First, it was not pre-specified and could have been influenced by
knowledge of the primary study results. However, we did not selectively present only results
that supported our conclusions. Second, we performed many tests of significance without any
adjustments for multiplicity. However, the level of evidence provided by almost all of these
tests (with p-values typically less than 0.001) would have withstood such adjustment. Third,
roughly 8% of all randomized participants contributed no psychosocial data. However, unless
the missing standard access participants happened to be much more inclined than the missing
increased access participants to have substituted EC for their usual contraceptive method, it
seems unlikely that these missing data could have negated our conclusions. Finally, asking the
EC psychosocial items in conjunction with providing unlimited access to EC might have
persuaded some women to substitute. However, these questions were not asked until the 6-
month visit, yet the data provide evidence of substitution prior to this visit, which implies that
such an effect could not entirely explain our results.
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Our results do not necessarily generalize to other increased access interventions. In particular,
providing women with unlimited free supplies of EC in advance of need, as we did, is certainly
much more aggressive than making EC available “behind the counter,” as is the current policy
in the United States. Furthermore, the increased risk that some women experienced as a direct
result of our intervention applies to unintended pregnancy only, not necessarily to other
undesirable consequences of sex. Specifically, the results from our primary analyses
demonstrated convincingly that women with increased access are not at appreciably greater
risk for sexually transmitted infections (5). However, although a new international guidance
(7; Chapter 3) encourages providers of family planning to, “if possible, give all women who
want [emergency contraceptive pills] a supply in advance,” our current results do suggest that
a policy of providing unrestricted advance access to EC could be detrimental for some women.
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Reproductive health item means at baseline, grouped by factor. An “*” indicates that the item
was reverse-scored prior to factor analysis. ECPs = “emergency contraceptive pills.” The item
“If you got pregnant now, would you have an abortion?” was scored from 1= “definitely” to
5= “definitely not.”
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Emergency contraception item means at the 12-month visit, grouped by factor. An “*” indicates
that the item was reverse-scored prior to factor analysis. ECPs = “emergency contraceptive
pills.”
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Table 1
Summary of Baseline Characteristics, by Randomization Group




 Nevada 431 (60%) 432 (60%)
 North Carolina 292 (40%) 285 (40%)
Age (years)
 14-15 34 (5%) 31 (4%)
 16-17 177 (24%) 156 (22%)
 18-20 259 (36%) 255 (36%)
 21-24 253 (35%) 275 (38%)
Hispanic ethnicity 113 (16%) 80 (11%)
Black race 74 (10%) 75 (10%)
Married 39 (5%) 37 (5%)
High school graduate 465 (64%) 490 (68%)
Any previous pregnancies 150 (21%) 178 (25%)
Had previous abortion 90 (12%) 113 (16%)
Used hormonal contraceptive method in month
prior to admission 360 (50%) 347 (48%)
Did not use hormonal method but used condoms
consistently in 2 weeks before admission 153 (21%) 144 (20%)
Any previous use of EC 233 (32%) 212 (30%)
Baseline reproductive health psychosocial factors
“Perceived contraceptive efficacy” 3.0 (0.4) 3.0 (0.4)
“Aversion to pregnancy” 3.5 (0.8) 3.5 (0.7)
“Access to contraception” 3.4 (0.5) 3.4 (0.5)
“Stigma” 2.4 (0.5) 2.4 (0.6)
*
Data reported either as frequency (%) or as mean (standard deviation).
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Table 4










 6-month visit 0.52 0.14 0.03 <0.001
 12-month visit 0.59 0.18 0.04 <0.001
 Used hormonal method at baseline 0.40 0.12 0.04 <0.001
 Used condoms consistently at baseline 0.50 0.17 0.07 <0.001
 Used neither hormonal method nor
 condoms consistently at baseline 0.84 0.22 0.07 <0.001
“EC relative benefit”
 6-month visit 2.19 2.01 0.03 <0.001
 12-month visit 2.16 1.99 0.03 <0.001
“EC accessibility”
 6-month visit 3.40 3.24 0.02 <0.001
 12-month visit 3.43 3.26 0.02 <0.001
 Nevada 3.41 3.29 0.02 <0.001
 North Carolina 3.42 3.19 0.03 <0.001
 Married 3.24 3.24 0.07 0.950
 Unmarried 3.42 3.25 0.02 <0.001
*
Estimated means adjusted for all variables listed in Table 1.
†
Includes only subgroups for which the associated interaction term was significant in the model.
‡
Standard error of the difference in means.
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